Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat Mesylate in R/R PTCL and CTCL
NCT06485219Phase 2Active, not recruiting
- Sponsor
- Zenitar
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of purinostat in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), sponsored by Zenitar. Started Apr 2024; status: active, not recruiting.
02
Drugs
purinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT06485219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485219.